Anni Nørgaard Jeppesen

Anni Nørgaard Jeppesen

Auto-generated profile, based on publicly available information

Anni Nørgaard Jeppesen

Anesthesia Section, Department of Cardiothoracic and Vascular Surgery, Aarhus University Hospital, Aarhus N, Denmark

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2010 in British Journal of Cancer
Verified
Journal Article
Open access
AJA N Jeppesen
A N Jeppesen
HJH K Jensen
H K Jensen
FDF Donskov
F Donskov
NMNiels Marcussen
Niels Marcussen
HMH von der Maase
H von der Maase
Background: Methods: Results: Conclusion:

1 April 2016 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
AJAnni Nørgaard Jeppesen
Anni Nørgaard Jeppesen
CCChristian Fynbo Christiansen
Christian Fynbo Christiansen
TFTrine Frøslev
Trine Frøslev
Henrik Toft SørensenHenrik Toft Sørensen
Henrik Toft Sørensen

4 May 2016 in Trials
Verified
Journal Article
Open access
PDF file
HKHans Kirkegaard
Hans Kirkegaard
BRBodil S Rasmussen
Bodil S Rasmussen
IHInge de Haas
Inge de Haas
JNJørgen Feldbæk Nielsen
Jørgen Feldbæk Nielsen
SISusanne Ilkjær
Susanne Ilkjær
ESEldar Søreide
Eldar Søreide
The application of therapeutic hypothermia (TH) for 12 to 24 hours following out-of-hospital cardiac arrest (OHCA) has been associated with decreased mortality and improved neurological function. However, the optimal duration of cooling is not known. We aimed to investigate whether targeted temperature management (TTM) at 33 ± 1 °C for 48 hours compared to 24 hours results in a better long-term neurological outcome. The TTH48 trial is an investigator-initiated pragmatic international trial in which patients resuscitated from OHCA are randomised to TTM at 33 ± 1 °C for either 24 or 48 hours. Inclusion criteria are: age older than 17 and below 80 years; presumed cardiac origin of arrest; and Glasgow Coma Score (GCS) <8, on admission. The primary outcome is neurological outcome at 6 months using the Cerebral Performance Category score (CPC) by an assessor blinded to treatment allocation and dichotomised to good (CPC 1–2) or poor (CPC 3–5) outcome. Secondary outcomes are: 6-month mortality, incidence of infection, bleeding and organ failure and CPC at hospital discharge, at day 28 and at day 90 following OHCA. Assuming that 50 % of the patients treated for 24 hours will have a poor outcome at 6 months, a study including 350 patients (175/arm) will have 80 % power (with a significance level of 5 %) to detect an absolute 15 % difference in primary outcome between treatment groups. A safety interim analysis was performed after the inclusion of 175 patients. This is the first randomised trial to investigate the effect of the duration of TTM at 33 ± 1 °C in adult OHCA patients. We anticipate that the results of this trial will add significant knowledge regarding the management of cooling procedures in OHCA patients. NCT01689077

30 April 2016 in Critical Care
Verified
Journal Article
Open access
PDF file
AJAnni Nørgaard Jeppesen
Anni Nørgaard Jeppesen
HKHans Kirkegaard
Hans Kirkegaard
SISusanne Ilkjær
Susanne Ilkjær
AHAnne Mette Hvas
Anne Mette Hvas
Coagulation can be visualised using whole blood coagulation analyses such as thromboelastometry and platelet aggregation tests; however, the role of temperature in the analyses is ambiguous. The aim was to examine whether temperature influences the whole blood coagulation tests. We included 40 patients treated with targeted temperature management (33 ± 1 °C) after out-of-hospital cardiac arrest. The blood samples were obtained on hypothermia and normothermia. Each blood sample was analysed simultaneously at 33 °C and 37 °C by thromboelastography (ROTEM®) employing the assays EXTEM®, INTEM®, FIBTEM® and HEPTEM®, and by Multiplate®Analyzer, using COLtest®, ADPtest®, ASPItest® and TRAPtest® as agonists. Data on antithrombotic drugs were collected systematically from medical records, and data were analysed using repeated measurement analysis of variance (ANOVA). The ROTEM® analyses showed increased clotting time, lower maximum velocity and increased time to maximum velocity (all p values 0.09) analysed at 33 °C and 37 °C, independent of the body temperature. In the hypothermic blood sample, no difference was found when using the COLtest®, ASPItest® or TRAPtest® to compare platelet aggregation analysed at 33 °C and 37 °C (all p values >0.19), but platelet aggregation was significantly higher using the ADPtest® (p < 0.001) when analysed at 33 °C. In the normothermic blood sample, the TRAPtest® showed no difference (p = 0.73) when performed at 33 °C; however, significantly lower aggregation was found using the COLtest® and ASPItest® (all p values <0.001), while a higher aggregation at 33 °C was found using the ADPtest® (p = 0.003). ROTEM® analyses seemed not to be dependent on body temperature but showed a slower initiation of coagulation when analysed at 33 °C compared with 37 °C. The Multiplate®Analyzer results were dependent on the temperature used in the analyses and the body temperature. In whole blood coagulation tests, the temperature used in the analyses should be kept at 37 °C irrespective of the patient’s body temperature being 33 °C or 37 °C.

1 January 2019 in Resuscitation
Verified
Journal Article
Closed access
LELars Evald
Lars Evald
KBKolbjørn Brønnick
Kolbjørn Brønnick
CDChristophe Henri Valdemar Duez
Christophe Henri Valdemar Duez
AGAnders Morten Grejs
Anders Morten Grejs
AJAnni Nørgaard Jeppesen
Anni Nørgaard Jeppesen
JNJørgen Feldbæk Nielsen
Jørgen Feldbæk Nielsen

1 September 2017 in Resuscitation
Verified
Journal Article
Closed access
AJAnni Nørgaard Jeppesen
Anni Nørgaard Jeppesen
AHAnne-Mette Hvas
Anne-Mette Hvas
CDChristophe Henri Valdemar Duez
Christophe Henri Valdemar Duez
AGAnders Morten Grejs
Anders Morten Grejs
SISusanne Ilkjær
Susanne Ilkjær
HKHans Kirkegaard
Hans Kirkegaard